0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Galectin-3

Galectin-3

Galectin-3 Molecule Information

Name:Galectin-3
Target Synonym:Galactoside-binding protein,GALBP,Epididymis Secretory Sperm Binding Protein,MAC2,Laminin-binding protein,CBP 35,Gal-3,IgE-binding protein,Carbohydrate-binding protein 35,L-31,Lectin L-29,LGALS3,Advanced Glycation End-Product Receptor 3,Lectin, Galactosid
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Galectin-3 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GA3-H5247 Human Human Galectin-3 Protein, His Tag
GA3-H5247-structure
GA3-H5247-sds
GA3-H5129 Human Human Galectin-3 Protein, His Tag
GA3-H5129-structure
GA3-H5129-sds

Galectin-3 Molecule Synonym Name

Galectin-3,LGALS3,MAC2,Gal-3,35 kDa lectin,CBP 35,GALBP,IgE-binding protein,L-31,Laminin-binding protein,Lectin L-29,Mac-2 antigen

Galectin-3 Molecule Background

Galectin-3 (Gal-3) is also known as LGALS3, 35 kDa lectin, Carbohydrate-binding protein 35 (CBP 35), Galactose-specific lectin 3, Galactoside-binding protein (GALBP), IgE-binding protein, Laminin-binding protein, Mac-2 antigen, Lectin L-29. Galectin-3 is a member of the lectin family. LGALS3 / Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. LGALS3 / Galectin-3 has been shown to be involved in the following biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis.

Galectin-3 References

Galectin-3 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ocriplasmin A-01016; THR-409 Approved Thrombogenics Jetrea, Jejetrea EU Retinal Diseases s:4:"null"; 2012-10-17 Vitreous Detachment; Disease Progression; Arterial Occlusive Diseases; Tissue Adhesions; Retinal Diseases; Stroke; Diabetic macular oedema; Symptomatic Vitreomacular Adhesion; Eye Diseases; Venous Thrombosis; Macular Degeneration; Diabetic Retinopathy Details

Galectin-3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TD-139 TD-139 Phase 2 Clinical The University Of Edinburgh, Lund University Foundation Idiopathic Pulmonary Fibrosis Details
Gal-400 Gal-400 Phase 1 Clinical Galecto Biotech Non-alcoholic Fatty Liver Disease; Liver Cirrhosis Details
Belapectin GR-MD-02 Phase 3 Clinical Galectin Therapeutics Non-alcoholic Fatty Liver Disease; Fibrosis; Hypertension, Portal; Psoriasis; Hepatic Insufficiency Details

This web search service is supported by Google Inc.

totop